Publication: Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient
Loading...
Open/View Files
Date
2013
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Abhyankar, Anita, Elliot Tapper, and Alan Bonder. 2013. “Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient.” Pharmaceuticals 7 (1): 18-28. doi:10.3390/ph7010018. http://dx.doi.org/10.3390/ph7010018.
Abstract
Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.
Description
Other Available Sources
Research Data
Keywords
autoimmune liver disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, overlap syndrome
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service